文献速递前列腺癌

根治性前列腺切除术在寡转移性前列腺癌治疗中是否有作用?一项系统综述

Is there a role for radical prostatectomy in the management of oligometastatic prostate cancer? A systematic review.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2023-11-20

该系统综述检索2000年1月至2022年11月PubMed、Scopus、Embase和Cochrane中央对照试验注册库,纳入11项研究共511例患者(平均年龄65.5岁)。寡转移性前列腺癌行根治性前列腺切除术切缘阳性率59%,中位随访13至64个月,临床无进展生存3年56%至7年45%,5年特异性生存60%至80.5%、总生存78%至80%,Clavien≥3并发症0%至21%,尿失禁率14.5%。作者认为该手术在选定患者中似乎安全且并发症可接受,但因缺乏共识定义、证据级别低及现有比较和回顾性研究存在偏倚,无法给出实践推荐,目前转移灶手术仅应在临床试验参与范围内进行。

要点

  • 寡转移性前列腺癌行根治性前列腺切除术切缘阳性率为59%。
  • 5年特异性生存60%至80.5%,5年总生存78%至80%。
  • Clavien≥3并发症0%至21%,尿失禁率14.5%。

核心结论

  • 与已发表研究相似,选定患者中寡转移性前列腺癌的根治性前列腺切除术似乎安全且并发症可接受。
  • 缺乏共识定义、证据级别低及现有比较和回顾性研究存在偏倚,无法给出实践推荐。
  • 目前转移灶手术仅应在临床试验参与范围内进行。

研究设计与样本

  • 系统综述,检索PubMed、Scopus、Embase和Cochrane中央对照试验注册库,时间范围为2000年1月至2022年11月,遵循PRISMA指南。
  • 文献检索共384篇,纳入11项研究、511例患者,平均年龄65.5岁。

主要发现

  • 切缘阳性率为59%。
  • 中位随访范围13至64个月。
  • 临床无进展生存率3年为56%,7年为45%。
  • 5年特异性生存率范围为60%至80.5%,5年总生存率范围为78%至80%。
  • Clavien≥3并发症范围0%至21%,尿失禁率为14.5%。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为目前转移灶手术仅应在临床试验参与范围内进行。

局限性

  • 缺乏共识定义。
  • 证据级别低。
  • 现有比较和回顾性研究存在偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: There is a growing interest about the role of radical prostatectomy (RP) in local cancer control in oligometastatic prostate cancer (PCa). PURPOSE: To evaluate the oncological and functional outcomes of RP in the management of oligometastatic PCa through a systematic review. METHODS: A systematic review search was performed and the following bibliographic databases were accessed: PubMed, Scopus, Embase and the Cochrane central register of controlled trials were searched from January 2000 to November 2022. This was carried out by the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) guidelines. RESULTS: Based on the literature search of 384 articles, 11 (511 patients) met the inclusion criteria (mean age: 65.5 yr.). Positive surgical margins were 59%. Median follow-up ranged from 13 to 64 months. Clinical progression-free survival ranged from 56% at 3 years to 45% at 7 years. Specific and overall survival rates ranged from 60 to 80.5% and 78 to 80% at 5 years, respectively. Clavien ≥3 complications ranged from 0 to 21%. The urinary incontinence rate was 14.5%. CONCLUSIONS: Similar to published studies, RP of oligometastatic PCa appears to be safe with acceptable morbidity in selected patients. The lack of a consensual definition, the low level of evidence and the bias of the comparative and retrospective studies available do not allow practical recommendations to be made. There is currently no place for metastatic surgery outside of participation in a clinical trial.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Saouli A, Touzani A, Martini A, et al. Is there a role for radical prostatectomy in the management of oligometastatic prostate cancer? A systematic review. Prostate Cancer Prostatic Dis. 2023. PMID: 37985863. doi:10.1038/s41391-023-00752-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。